Alison Stopeck

Alison Stopeck led the landmark phase 3 trial demonstrating non-inferiority of denosumab versus zoledronic acid for prevention of skeletal-related events in breast cancer bone metastases. Her research has contributed to defining optimal bone-targeted therapy selection and monitoring in metastatic breast cancer. She investigates biomarkers of bone turnover and predictors of skeletal events. She has shaped national guidelines for bone health management in oncology and is an active educator in the field of supportive oncology.